Australian Drug Regulators Consider Order To Withdraw GSK's Avandia
This article was originally published in PharmAsia News
Executive Summary
Australia's drug regulator is considering removal of U.K.-based GlaxoSmithKline's Avandia (rosiglitazone) from the national market because of a link to heart attacks